{
  "actions": [
    {
      "acted_at": "2019-03-05",
      "action_code": "10000",
      "references": [],
      "text": "Introduced in Senate",
      "type": "action"
    },
    {
      "acted_at": "2019-03-05",
      "action_code": "",
      "committees": [
        "SSHR"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Read twice and referred to the Committee on Health, Education, Labor, and Pensions.",
      "type": "referral"
    }
  ],
  "amendments": [],
  "bill_id": "s660-116",
  "bill_type": "s",
  "by_request": false,
  "committee_reports": [],
  "committees": [
    {
      "activity": [
        "referral"
      ],
      "committee": "Senate Health, Education, Labor, and Pensions",
      "committee_id": "SSHR"
    }
  ],
  "congress": "116",
  "cosponsors": [],
  "enacted_as": null,
  "history": {
    "active": false,
    "awaiting_signature": false,
    "enacted": false,
    "vetoed": false
  },
  "introduced_at": "2019-03-05",
  "number": "660",
  "official_title": "A bill to address abuse of the Food and Drug Administration's citizen petition process by brand drug manufacturers.",
  "popular_title": null,
  "related_bills": [],
  "short_title": "Efficiency and Transparency in Petitions Act",
  "sponsor": {
    "bioguide_id": "B001310",
    "district": null,
    "name": "Braun, Mike",
    "state": "IN",
    "title": "Sen.",
    "type": "person"
  },
  "status": "REFERRED",
  "status_at": "2019-03-05",
  "subjects": [
    "Administrative remedies",
    "Department of Health and Human Services",
    "Drug safety, medical device, and laboratory regulation",
    "Government information and archives",
    "Health"
  ],
  "subjects_top_term": "Health",
  "summary": {
    "as": "Introduced in Senate",
    "asOf": "2019-03-05",
    "date": "2021-09-13T15:23:16Z",
    "text": "Efficiency and Transparency in Petitions Act\n\nThis bill requires a petition regarding a pending generic drug or biological product application to be submitted to the Food and Drug Administration (FDA)within one year of when the petitioner discovers the issue that is the basis for the petition.\n\nThe FDA may grant a waiver of the one-year deadline."
  },
  "titles": [
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Efficiency and Transparency in Petitions Act",
      "type": "display"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Efficiency and Transparency in Petitions Act",
      "type": "short"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "A bill to address abuse of the Food and Drug Administration's citizen petition process by brand drug manufacturers.",
      "type": "official"
    }
  ],
  "updated_at": "2022-11-01T17:03:24Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/116/s/BILLSTATUS-116s660.xml"
}